Skip to content
Screener

Celcuity CELC Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$25M
CTO
Citius Oncology, Inc.CTOR

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.43B+131%
Enterprise value$4.42B+124%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Celcuity’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-023180
Line itemMarch 31, 2026December 31, 2025
Total liabilities356,639366,003
Commitments and contingencies (Note 6)--
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,500,000 shares authorized as of March 31, 2026, and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026, and December 31, 2025
Common stock, $0.001 par value; 95,000,000 shares authorized as of March 31, 2026, and December 31, 2025; 48,347,390 and 48,244,960 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively4848
Additional paid-in capital555,215549,404
Accumulated deficit(501,738)(448,897)
Total stockholders’ equity53,525100,555

Item 1. Financial Statements (unaudited) ITEM

FAQ

What is Celcuity's preferred stock, shares authorized?
Celcuity (CELC) reported preferred stock, shares authorized of $2.5M in Q1 2026.
How has Celcuity's preferred stock, shares authorized changed year-over-year?
Celcuity's preferred stock, shares authorized decreased by 0.0% year-over-year, from $2.5M to $2.5M.
What is the long-term trend for Celcuity's preferred stock, shares authorized?
Over 5 years (2020 to 2025), Celcuity's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $2.5M to $2.5M.

Ask your AI about Celcuity's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude